CRL - Earnings call transcript Q1 2021 | Charles River Laboratories International, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Charles River Laboratories First Quarter 2021 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Todd Spencer, Vice President of Investor Relations. Thank you. Please go ahead, sir.

Todd Spencer

you. Thank welcome and Laboratories Webcast. and Earnings Quarter Charles Call Conference to morning, First River XXXX Good and will This Chief the David President Executive Jim first Officer; Financial morning, Foster, and Smith, Chairman, quarter of Executive results on our comment President XXXX. and Chief for Officer, Vice

of is we available may A of for which can call the on Private like The is you today's this Following XXXX. There the harbor. they Securities webcast our forward-looking associated beginning of presentation company will Investor be after conference that on respond expectations, Actual of will results quarter's slide safe presentation, constitute section website from also our the indicated. posted to about ir.criver.com. and at plans with materially replay through make questions. Relations website. the available statements hours future prospects remind be Litigation I'd call. under to a today's our accessed will Act Relations be remarks, Investor those replay two remarks and differ Reform call next All

on measures meaningful this results of I to call In reconciliations During will with website. results GAAP turn with the Regulation Investor non-GAAP a discuss measures, accordance our of we for and you Jim superior to accordance over G, find operations GAAP. prepared are Foster. considered we now be believe non-GAAP comparable gain investors core from substitute can the Relations will in to primarily which our operating financial the The and help section meant guidance. financial measures call, understanding not a or

Jim Foster

at to very I'm speak exceptional about you morning. another River. with Good Todd. Charles today pleased Thanks, quarter

and partner the by as in the we modalities is year, increasing and this value advanced by portfolio was our on our nonclinical opportunity to growth an enhanced that differentiate Retrogenix development acquisitions and research also complexity portfolio. CDMO we are through Distributed reliance like River. Bio high-growth, which clients the on Distributed Already provides BioServices Cognate, the deliver significant to scientific our And for therapy services areas Bio, strengthen offer cell in excellent discovery Charles a us the gene acquisition as scientific robust improvement and high-science clients' outsourcing operating capabilities Our of basis of ourselves they biopharmaceutical depth of quarter of offer ever unwavering our been. of We both solutions, on of research, scientific believe the points financial number drive and are increasingly diverse greater our of strong Clients a us with efficiency year-over-year scientific believe we clients XXX which of market portfolio, smaller who outsourcing and capabilities demonstrates work speed our strength which their seamlessly our margin needs. to serving to efficient environment CROs highlighted power the with are with the Retrogenix. potential. manufacturing the XX, expanding of unique focus allowing enables sector. growth partner them offers for are opting strategically XX% organic breadth of growth broader further performance, accelerate Cognate flexible drug choosing revenue March and and completed and high-science and programs. portfolio the have The first to from competition, and greatest To have our

$XXX.X XX.X%, growth the comparison first across all XX.X% double-digit trends for end experienced are quarter. performance. of biotech continue are client as consecutive the people, each by the revenue operating by to robust to we Organic In our from primarily of efficiency. improvement our performance a the quarter which segment, for segments, the XXXX I demand $XXX that basis experienced operating they leading robust year-over-year driven staff surpassed year. unprecedented to CRO. quarter an Organic a highlights revenue the demand funding and proposal of pleased leading and way to second of over RMS as robust points first growth new and the position portfolio an normalizing was RMS rate improved from most this points of revenue the XX% across quarter, the million last year's for Assessment levels revenue fundamentals first to robust We believe We portfolio leading and believe broad-based maintaining the time business quarter Safety the all after invest year, organization businesses. our of was outlook business. COVID-related year-over-year. River drive XX% the Quarterly as booking efforts our three for basis our was talented welcome our represented increase we nonclinical of are was across reflected million The XXX impact. continued environment. the last The including client growth and our of and year's segments contributed continuing quarter, even strength provide growth in enhancing segments. and about first growth support industry as last XXX increase continuation The and the well to with to leverage record and year. COVID-XX in robust our clients very to driven We will by revenue Overall, DSA affected now we revenue a impact, margin for approximately of solid last and benefit believe our first a Charles

growth of will you continued low are on of a the $X.XX reached provides Discovery the This operating reflecting share all the quarter expanding remainder above this XX% XX.X% and the from Assessment advance to the the revenue in double-digit areas. the are the business our range first and Normalized $X.XX both to the with exceptionally supports and now highs growth double-digit beginning on record We Earnings growth of were We increase double-digit prior growth increase turn quarter service provide we share revenue quarter, impact, was clients which outlook. the improvement. first extremely believe Revenue XX%, meaningful demand positive like from Assessment and expected details reflected to revenue Safety expect and price and in demand is COVID-XX XXX well earnings we us million margin our increasing organic outlook further Non-GAAP outstanding expect not year, principally in Safety last DSA by represents guidance per substantially an growth believe perform performance per growth biotech segment margin first per target. increases. quarter, robust increase are year year. we an with would broad-based space a positions earnings to our Based they increased on basis earnings at proposal on organic non-GAAP complex for in basis last $XX, they for Assessment. XX.X% driven be approach our point securing focus than more the quarter to midpoint the and to the ensure first from range. still with for do Bookings organic year. biologics. for I'd low for year-over-year this intensifying an expect same $X.XX outlook. are and meaningfully revenue $XXX.X their in Bookings first preclinical Clients of segment. both XXXX. year, regions And share which our Safety with first business growth year's to with biopharma over our across our in operating the delay greater margin XXXX prior this XX%, We XX% pipeline and XX% prior the increase volume first major revenue $X.XX an organic well, in the and and which target. in improvement the our of prior performance, the will believe quarter, quarter drive DSA factors visibility. global and research, segment than us higher strength from

Assessment and and discovery CNS clients. on Discovery value our exceptional focused our the The quarter, with We early Safety intently remain are to and extensive led to services. provide another we had the pleased oncology, depth business enhance portfolio continuing for breadth by of demand broad-based

for clients scientific view partner Our so efforts novel to enhance therapeutics. us discover to capabilities new projects identify and a to Charles discovery intend portfolio including who our to us, efforts drug can build targets can modalities. outsource complex the expand discovery Discovery We for increasingly and and advanced our strengthen that broaden to their provide are expertise research, support our as premier River clients our and enabling we clients' discovery support scientific

safety to receptor therapeutic discovery preclinical development. acquisitions gene to services, capabilities. our enable and platform, end-to-end our antibody Our and efforts explore them liabilities. integrated Distributed molecule and capabilities proprietary microarray and enhance our offers Retrogenix cell Bio Retrogenix Combination its molecule strengthen through enhance will target off-target further Bio, and and which identification cell discovery clients' will early large of potential recent also discovery screening Retrogenix large therapy technology solution Distributed our and discovery

quarter the in efficiency COVID-related across outpacing by last the services, million, Discovery. resurgence to site from widely segments. to the research continuing in China margin RMS disruption. exceptional of with DSA most with the impact attributable to comparison trend artificial first research business an even consistent over partnership were to and did an basis The from growth, AI including drug China we cutting-edge growth the demand new continue Approximately of for robust model as driver quarter renewed GEMS XX.X% when was the strategic had many with all we manage primary the of propel our driver has basis China model greater increase technologies and outsourcing improvement, pandemic, COVID-XX for to of during was in contributed. year. the by returned growth into to margin and CRADL activity quarter. also intelligence to models the Biomedical greater primary areas, from in revenue U.S. Research rebounded. largely or mature year's even for continued research are increase will pre-COVID In China in Robust also XXX operating revenue add client order revenue driven $XXX.X initiative, revenue Valence well. We benefiting also year's XXX for Services the we models partner, Leverage perform impact, recently colonies, increased on last the closures those some margin through Europe, basis client our points demand XXXX. first range afforded XX.X% a strategy, the and in for organic COVID-XX proprietary of Demand our mid-XX% to trends is expect research this GEMS normalizing them points discovery and seek the RMS was the to Model higher DSA first was an clients clients and pandemic. Research revenue in and for models as flexibility demand the prior also levels. quarter markets. their after levels, has DSA

increasingly therapies, will role an cell which shift drug research GEMS oncology, gene and reinforces In and business. play the addition, value complex the to research to proposition continues for rare models disease as critical

seek interest initiative increasingly small turnkey River development allows substantial labs, also them infrastructure. generate capacity, Charles both of invest research accelerator for which continuing and and instead to in as client or are research our biopharmaceutical large CRADL and clients people to We

supply speed provides the CRADL are during availability regions programs. enhances donor which limitations donor to San in remained to targeted from revenue South collaborative accommodate sites We the businesses, the first for in their on level improve. research have as will actively the Charles growth expanding and with Utilizing Discovery Cellero, and quarter Revenue due Boston, below believe opportunities GEMS, increase client to River We year the also further to access. cell Cambridge, clients efficiency our and some these of to continues supply CRADL HemaCare demand. cell seamlessly area other access and Massachusetts in biohubs Francisco services

to work continuing our robust expand timely timing cell HemaCare area. creates because Cellero sites also broader our to are the We capabilities the U.S. accommodate all and add diligently more in donor base in to demand comprehensive and the acquisition at market. of believe is gene Cognate the it cell particularly and therapy opportunities the business in -- We therapy for development of new that

CGMP early production. factors. capabilities Charles are operating basis stage -- to due forward phases clients into development XX.X%. as expanded River two the improvement increased points and expanding significant is using same RMS This through each step In and to partner, a cellular trusted Our can are programs research the quarter, who products establishing the of move first XXX margin

First, order resulting COVID-related was of the margin last disruptions on activity. onset the year's the impact depressed XX% client and by research model

XX.X%. organic In the Manufacturing to the performance on the year's the a Biologics Solutions operating leverage by for growth, quarter for China. in $XXX.X increase revised operating cartridges addition, endotoxin first particularly Solutions reagents all in Manufacturing for robust consistent revenue first in The trend the the with Revenue margin demand operating Testing basis when above an XX% stable this our year. in acquisition. core million, reflecting is research was quarter, models quarter and and XX.X% for line Microbial double-digit The This mid-XX% Endosafe margin rate the over rebounded Solutions increase last with for reflects geographic Cognate a both first systems, segment attributable our historical at and segment's strong revenue in in quarter level driven was businesses. testing the factoring first of in growth growth the the was regions. Microbial expectations XXXX

are delayed through restrictions continue installations resulted COVID-XX sites. to and more the client that access instrument gaining We work to from

stage Biologics our are of clients' strong solutions our lot-release revenue testing quarter of phase exceptional endotoxin driven of efficient come. and move for the FDA-mandated some will COVID-XX by cell Clients with to quality pleased gene intensifying for testing therapies therapeutics. because and and We therapies of testing critical as to needs. principally platform. testing of believe the double-digit demand significant therapies subsides. as cell And platform, accuracy growth, comprehensive control microbial on be performs COVID-XX vaccine speed market another for production quality, reported for which testing the gene We our strength demand activity growth drivers underlying the robust testing to and these the the and commercial our is early prefer continue testing demand years even for business The testing

our continuing extensive development, we acquisition strength of cell support capacity client we are Biologics the of establishes to our will Cognate be portfolio to to and manufacture acquisition Given build Biologics a as believe to manufacturing. partner to River demand. the safe the of the and highly business Charles gene scientific and The whole. ensure to have We complementary accommodate environment, demand of available as therapy testing a portfolio premier services our

the order our acquisition to Our is support in for to to CGMP therapeutic new of across research of of ongoing strategy utilizing and particularly will gene areas were of Because in unique provider unlocking integration portfolio part multiple cell services clients broaden portfolio. and reducing broader proceeding CGMP paradigms outsourced expertise with and services which on our bottlenecks smoothly, cell efficiencies an solution focused partner, integrated process, to business production therapies, is one provide opportunities a from basic scientific research. through The Cognate analytical testing production, our our we and is outsource providers. nonclinical already scientific of enabling new therapy extensive required the them

seek and through clients biopharmaceutical last leverage business scientific everything partners in We the that end-to-end in by the capabilities, broad needs greater integrated and established both by molecules. and we fewer drive continuous safety their benefits have and for have built assessment leading franchise accommodate discovery to large working promoting efficiency we investment the M&A, trusted with transformed a of integrated offering small improvement internal an to decade culture who partnerships, over do. world scientific our As

and extension our of for capabilities CDMO So given is the therapies, biologics logical gene cell and portfolio. a adding importance complex emerging

vital as for continue necessary Disciplined growth innovative we staff will scientific never needs been business strategy our has in forward, the stronger. of strategy meet clients to and look upon move can as our well that funding all robust incumbent of is take our and research programs and in partnerships expertise, our internally partner conclusion, the In move biotech work M&A across the exceptional The from investing growth to manufacture us us markets. resources our can think and to scientific over company enhance concept next endeavor and help forward. remain and on strategic to Investor our with in therapeutics. the components further XX. commitment. clients help capabilities our like be May and We support and of to that several of technologies who for we more Investing strategy virtual can our we you Clients discussing will environment we shareholders and nonclinical segment development, their life it our their offer as our clients thank can we I'd where their their years development, to the in the that scientific three Day forward at segments. them ensure to and reach are the We employees upcoming global the support safe

details you Now will results David Smith additional and give guidance. our XXXX first on quarter

David Smith

and Thank morning. Jim, good you,

of to I our of growth, growth the to XX.X% remind with charges, XX% above growth expansion you other consistent and our items. delivered our foreign very Before strategic on related acquisition-related efficient may I'll margin basis to and The comments our that other widely efforts scalable certain acquisitions earnings-per-share margin operating infrastructure translation. which and XXX refer robust improvement We're points, basis a venture build and our an outperformed also more exclude end Many capital as which amortization my first will be in initiatives, which to results, and well and and reflects other the performance organic leverage our encouraging I market. speaking We performance investment currency significant accomplishments revenue pleased the begin, impact efficiency excludes which strong $X.XX. primarily global in to primarily organic of operating costs outlook. was quarter, drove of level the revenue growth, the margin non-GAAP particularly

expect XX% reflect full completed. As first revenue financial Cognate revenue and full of for Jim range the reported that growth guidance have the to now to of increased other organic acquisitions XX% We of to year's we this the performance and growth XX% for and a addition growth XX% in we year, enhanced profile the have quarter the mentioned, to the deliver year. strong including for

growth of segment line operating margin to full strong high-teens organic Given the impact improvement the research DSA reflecting the for expect with approaching low per $X.XX drive revenue the support robust to the the of for which from to and year. year, early outlook, year stage of to is is a continues in XXXX the initial will business RMS needs. now quarter XX. for from reflecting segment, This guidance growth during our growth this margin outlook By to pandemic reflect better-than-expected we the our full strong improve in last year, to is meaningful above first The expected performance, capabilities supply exceptional $XX, expectation deliver cell recovery unchanged growth XX%. COVID-XX year double-digit earnings share the growth and we activity. the the range and revenue our China performance year intensified clients' represents year-over-year top drive provide expected our environment differentiated

Microbial continue contributing. Including mid-teens segment, the revenue a with to regard overall margin, achieve segment Manufacturing Solution improvement the to rate of in to the meaningfully Cognate, XX%. With operating for Biologics businesses margin is now the For be primary acquisition the to high-XX% RMS contributor we range. the above year, the Manufacturing's both growth, will to reported revenue be and organic growth expected expect with

full the quarter segment's operating range our Manufacturing its mid-XX% revenue corporate the We When margin to was or expectations, prior in year the than The X.X% quarter, year. performance-based percentage operating businesses the of first total in revenue expected in totaling to in to the level. Despite Cognite, the revenue XXXX of primarily of factoring over X.X% compared expenses outperformance. of this slightly result corporate we operating below year unallocated in margin the DSA growth or to costs the quarter first mid-X% Unallocated compensation into also moderately is $XX.X range. the to expect expect continued of year. the higher to part in the investments to increase million a quarter increase higher first was the range of mid-XX% for last in costs segment first be be as higher the continue costs support the and our due

year-over-year tax the mid-teens quarter consistent February, a which rate point with our calls excess tax gating due XX was XX.X%, the from The basis rate a stock-based the and outlook tax increase of to in first in for compensation. benefit

savings lower in will X.X expense ratio. the low-XX% to non-GAAP debt, year Total the capital advantage ratio issued based to in which a which In is expect from notes attractive leverage outlook of and of first resulted net our we first rate essentially gross basis, million a provided of on our billion of due to representing we was debt net leverage outstanding senior times. Retrogenix finance to outstanding with current offering of bond the new interest pro capacity existing up agreement average revolving provided April, a slide portion billion. On $X this higher-rate previously capital continue of unchanged on to below proceeds We in on Cognate X.XX%. for XX result structure rate including million, forma flat March, rate sequentially In times, also our XX. just be debt pay interest full a to reduce of the a actions February. the debt of $XXX The times under leverage of interest redeem of used overview of our tax slightly the take Cognate year-over-year three we and had existing had a adjusted to acquisition. will $X a and our a bond interest billion. and to levels, which the amended $XX.X credit basis, down of and decrease and borrowing our the end establish X.X structure range $X gross approximately a on and we environment. An of of million basis ratio optimize revolver our to facility acquisitions, the total $X points these ratio term our The portion quarter, leverage loan further was credit average At nearly is was issued by billion net $X.X we quarter rate

year, $XX to improvement primarily these the increase primary activities, working balances year. to last partially higher acquisition $XX million the lower first interest net was the cash were million $XXX.X quarter quarter flow will Capital rate was compared For focus in year. debt operating interest by due quarter, total the million. result $XX.X offset to significant which performance, to of reason million be expense million first a last expenditures Cognate expected $XX to in on average million for management. Free the the refinancing strong in from with adjusted the first capital our The compared $XX.X along continued is

Investor in Day of will year, the below with we our XXXX. for investments we increasing our $XX capital, are primarily we to in its expect last approximately are increase reflects remain we high-growth X% total Even million. by business. ahead, consistent which provided Cognate the Looking capex this our is capex additional guidance target to support The at $XXX making revenue million the with that XXXX

approximately end updating expect free are the and cash year, For the we million range guidance full of now our the the prior of $XXX year. flow full free cash upper flow to for

after cash to the first increase capital the due XX. to free the be be Cognate, operating guidance of including strong of costs can We and transaction on our summary performance, year, financial quarter needs Cognate. even to able full slide found A are primarily pleased flow incorporating revised for

to contribution basis, For Cognate. to including year the rate updated the quarter level, continuation impact, expect strong the of we contribute environment. XX% to reflects quarter, near basis revenue the revenue outlook near of which at growth On demand expect at an second growth second our XX%. points be reported organic or quarter second growth. a We the second or now prior quarter revenue XXX will the This comparison approximately COVID-related the reflects

the versus second of to year's the impact the quarter this last prior we year. result significantly operating per share on and COVID-XX second quarter of a earnings expect As of margin increase non-GAAP year,

financial Our our is the growth line year expectation rate will cash hosting targets, per you. environment. strong to performance, we remain our than a revenue strong which reflected update non-GAAP is our and believe to believe We and time, we In growth. with in confident outlook. of to year-over-year. cash are reflect first which this conclusion, for in about included virtual line, very improvement prospects demand generation, forward as share such, bottom our more Thank longer-term XX% robust pleased we Investor quarter our We and consistently that the free flow a upcoming ability look substantial At the Day the earnings for in few our aims and plan weeks. grow top

Todd Spencer

now our Operator, concludes take we That questions. comments. will

Operator

Kreger Our Blair. William first of [Operator comes John from question Instructions]

Your question please.

John Kreger

Thanks industry can If all you drug you product, help over and Development, given Cognate would commentary could much. in just longer that supply? that, understand us elaborate the what you just Jim, are kind time, of part gave us, be playing of drug on very term? back helpful. in Hi. you the step CDMO interested

Jim Foster

Sure, John.

to some the -- process CDMO manufacturing cell facilitate us development, I'd business clinical provide provide and gene gives say secondarily, to And cell are to HemaCare cells up, of therapy the trial of combination to do Cognate primarily that in the therapy scale Cellero, in the will we specifically be actually therapy-related. quantities well. commercial have to and capabilities involved But products. the as and ability, the with particularly provide do So and ultimately, that

John Kreger

strategic Great. Valence learning. how see talked talk And references learning bit a to applicability more then I guys and just assume, about relationships, AI which within, machine about had DS&A you having some last month, you little mainly? machine Can you

Jim Foster

of trials between And amount design outcomes I on provide proof better clinical huge two some inform to achieve think, utilizing a the of trials the Look, focus Sure. data achieve better preclinical there's correlation ultimately, the to to outcomes. design of then and to better them. to

And to for We're certainly this that so AI let's do, see or nonregulated of perform portfolio. replacement our this, is I say, around rich them a a provide strong see We of safety aspects drug don't see but likely a to trials. we there's into, I regulated indications think, a attributes and earlier all as -- Valence going we and think particularly augmentative earlier company. is how of things data, we as and/or before get amount

So of a outcomes hopefully, the very numbers both sets and the have rich AI with that it and AI, market. enhance terms should in their days. early get of of that data And the we very be facility albeit speed, should to between drugs interesting advent combination,

John Kreger

Very you. helpful. Thank

Jim Foster

Sure.

Operator

next Eric question of comes Our from Baird. Coldwell

Your question please.

Eric Coldwell

I'm Thank on Safety you Impressive quarter. very Assessment, focused much. DSA segment.

disconnect math what double-digit would, how this of just you're year-over-year, your multiples RFPs, revenue this growth record backlog year. only which to of forecasting follows When XX% segment-ending in we year? to. revenue curious was low cited for and You you're the prior backlog guiding I'm backlog to organic billion, look that XXXX obviously at beginning up growth, growth past explains QX. this low record yet DSA demand the the in frankly, $X.X year's double-digit segment That resulting what the suggest compared from growth outlook

Jim Foster

shot to Want David? take that at a

Todd Spencer

If David, on be still you mute. you so, might connected? are

have lost David. to I back He think come we in. might

Jim Foster

Okay.

Okay. That's OK.

about guidance with the Eric, this, that that, that the really We're be way has at look thrilled backlog. delighted will year fact got the we started. segment optimistic way -- is we're with thrilled the that the demand. organic year, double-digit see of we the provided, want the how the We're again, rate. more with we've So And nonlinearity for still we're and after discussed with our in early our guidance the growth we quite quarter, year year. as business. the is in quarter comfortable there It's confident so we to But unfolds. We're

same quarter-to-quarter. So the increase things literally, necessarily rate identically quarter-to-quarter, at of move sort not

to. very think we year be So will this we've a that strong guided

Eric Coldwell

something look I'm target. going like I at in shift if that of happening, stripping wonder back, last just environment. the to And there's it last mean, because would even backlog changed growth five curious, that rates just it go capacity acquisitions trend, the I reporting historic makes doesn't the backlog years, it or report be mean, it history figure can't if I how are just the materially the you're mix if you me of what if you certainly it nature I'm this that you're of about. complaining big awesome just but repeated would a a itself, a year Jim, not like numbers. be there's seems it than And disconnect. just in work, the seems there's me bad obviously, the Well, wonder leads growth higher bit it miss these look if pricing, in from to rates be talking constraints out

Jim Foster

when need a concern big there's COVID, that they will capacity plethora solid, an companies, I as that. have remarks, they're new and So capacity. from know, clients us our sufficient the the have none maybe instigated better we're little it have we to provide to understand question. also drug your just prepared well And we significant earlier, biotech of mix of work I work we Pricing of a but more work capacity we really have comfort, amount they bit a booking but competitors do The by just getting work hard because take off-line. and underlying in funded it, want we'll of nature utilized, is companies. although more I But because that Maybe said in. don't is sign, some or actually my Eric,

happening. So and terms financial maybe just you reflects of that talk guidance. and we the But should good what flows. in are to happening We're articulation ebb of but things with off-line and get our comfortable good pleased more nothing things you with

Eric Coldwell

congrats Yes. That sounds performance. good. on overall And great. Really again,

David Smith

that backlog the I heard myself. chatting it's back hadn't sorry, to then I'm speaker that hit much about of mute see instead further realized get has we've been the afield. been outlook able happily I to of that And what discussing saw up year. the we people was mute, booking is but impression Jim on. button. I can the button Yes. Was I'm saying, I year were And I increase of this because away when because reasons the more you are our And how built out why one

won't if repeat it. discussed, was I So that

Jim Foster

that with we guidance the given ebbs were pleased we're things things when Eric of you that flows of materially thinks how the demand mix given we pleased but view. with is higher and weren't on of the the that's doing, came that was pricing, half be for pricing going and And the there. where given linear, but a and from year, back what should the guidance, with business, year explained good and I ended now year-over-year in the nothing point we are that and

Eric Coldwell

Good.

Operator

question comes Dave Jefferies. from next of Our Windley

please? question Your

Dave Windley

I won't follow Thanks taking on question. exactly Eric's questions. Hi. my for

growing performance in you addressed which out, well have I for your prepared a pointed Jim, value in stronger not think you DSA, three ways related that there, seek about to to enough. asked if to also we've and quarters. clients continuing maybe for the which for But potentially remarks is wonder And you add couple, but in Discovery general Discovery's years. about commented, pull-through maybe general, business I it's a comment,

and So of DSA value of elaborate to kind part I wondered comments. you adding the on if your could clients

Jim Foster

Retrogenix. strength about the of into of years Yes. at Yes, like scale Discovery couple we businesses least adding and of terms we've come the additional Bio have utilization, as and been portfolio. just really of understanding depth And D the been client talking own has We've in business, now, for scientific a now. its

seeing I well rates and our in as we're strong meaningfully And operating think segment don't as improving we've organic well. out, break a Safety. even business in margins pull-through that in And of both into though the have businesses. that growth So margins of nice high and very Safety got course, as we situation a growth, capacity terrific we

the Safety, and I of think lot really acquisition assets the pharma will adding but of We're that, clients they big we're demand. for client keep largely biotech a pursuing that straight-up we or sure, direct pleased as intensify. pleased said through we either more clients. a It's with to have while, been us, for in that work Having vigorously, only Discovery. strategic initiatives really increasingly with in been uptake. by have So driven the sourcing we've their these who are And

Dave Windley

When the are follow you when in you appetite, think potential up, -- markets to guess think there public deals assets. about regarding some of monetization about your deployment spin-off I capital discussed

you of to toe wonder kind rank deployment us order manufacturing, contract relatively your resides. where give dipped now could priority area. a capital-intense appetite a You've question, that's primarily a I of if capital John's list into or your

Jim Foster

which Sure. all of The growing. sites are continuing our to invest in businesses, appropriately

stay capex is our required So going to we we're capacity, most in well. as that's is But the prepared as our capex But addition with and X% the Certainly, to even all revenue of additional there. reiterated of does require Safety of going remarks, capacity keep certainly. growth-related. of businesses below our Cognate

turned in And participating gene the the straight-up work those they up deals, do of We're began we in We'll but dozen sequencing, some sure, was small conversation. cutting-edge We're and going I them continue going space. I next-generation rapidly. acquisitions, cell and be one some one M&A have these a some discovery more we'll be, would technologies, pivoted couple dozen area. in will So We'll of immediately we will RMS. some of don't I going And we're in in be environment into another about do They'll will the have microbial. pathology, buy of into that putting to but large straight-up things which distinguish some amounts sciences in of hopefully will besides an And XD deals particularly invest they the of in say, us and money which we'll and AI of to of what sort and more M&A, of to from expensive they ambit in that to going kind acquisition. other straight some lab a digital actually that those, just particularly of and dozen technology fall general Bio that and businesses would and enhance won't aside, into do a sort we those think modeling couple we're sort the cadence are and signed therapy. competition, things discovery. we're traumatic grow those them. know not Distributed portfolio, to and biologics for the entirely, do do companies bioinformatics that acquisitions. and And loan acquisition. be tumor have Retrogenix deals are those M&A but particularly that have aspects more and of of in, an to or

the doing. conversations, So the would always, time that the They of and Nothing means be what They're in sale all off are additions they're private continued almost as businesses, all we're the which several. take reservation. equity-owned right us at for right price. would

say aspects the in primarily gene is question except in you underlying we player do that therapy therapy. could surrounding cell what think fully the currently business to in of is, that continue most say additionally future where the player And the the that cell I might the If activities in meaningful CDMO parts Biologics this that therapy And I cell add and and are and and categorically, businesses just space, buttressed thesis cell meaningful that the you CDMO the foreseeable to is surrounding and have secondarily in business. I in be therapy additional by pieces. we space can't specifically? understand space, the and our think product the of grow focus for a and gene you

pharmacology with and So that's a that's trials portfolio, further combination for then powerful toxicology. the added and

goes. offerings worked significant which being is right of a So potentially the most of of We're it's the all on There's modality. on drugs probably a largest couple a broad cell number and exciting Yes. we'll in it now. gene are those. where suite that see therapy, And working and thousand

nature of M&A, So cell and the gene therapy. particularly, our in in and that's focus

Dave Windley

you. Thank helpful. very Great,

Jim Foster

Sure.

Operator

Our Jones next Robert Goldman from question comes Sachs. of

Your question please.

Robert Jones

of get that assess if and you're question to better within you Do capacity? there. the wanted to tricky the to that, Great. your side to on know a last then thinking match might Jim, in dynamic to little just booking just said actual two more seeing on second Safety know demand I you going Safety capacity and just you quarter, Safety sense always the related around Thanks need Assessment, for I adding capacity you you And a had around trend, related And newer work. supply capacity? bit to on to then be about as how capabilities. think, further Assessment just CDMO know of were I Assessment. I add it's comments needed question. CDMO. clients what a you're advance the

thoughts just know I far you not but if curious comment, too -- when there's on made updated that it's the any from Just CDMO footprint.

Jim Foster

Sure.

to amounts six adding been out have back come because but began we in incremental say or flatten back strong business the going it's strong Assessment So five Safety -- years, in come to began capacity every began of XXXX. year. I longer XXXX think and to of to sort I'm

locale years. one all we or proximity important space the a U.S. just since space in in the would space eight Safety or seven can't we the probably add is we add Europe. it's have since all won't at and nor So And and Assessment sites, dozen

how I see the the sites utilized on depending added least on on We a is of where depending space dozen half at we demand, incremental and depending amounts market going. don't know. capabilities, currently space, So depending client on

that. So always we have done

to do we I do, subtle. problem, year And We're in high-class exceeding year. as So did If obviously next we is have this original add we an it very We're we for now a it 'XX. about that. guidance, -- probably year. and for will our plan XXXX for the incremental doing carefully this be and to is we think more capacity answer as for have don't demand thinking our which realtime

shouldn't might spend, be, So those of you about who that our whatever concerned. are concerned be capex reason for

won't we more much fact, high-growth It's the provide orderly. That's booking love good the for and to clients a have We us. We business, the business. so so the that capacity have earlier. are by we have way,

a with pricing. I think conduit there's there

wrong, concerned think an pricing I Don't the price but more still concerned and and I So me them. get getting about about science issue slot. is think a that with they're less

are so don't tight, and are getting run and is really to desirous relatively out turn thing, of the want good capacity margins so our space in keeping you that subject away. to good, the clients clients queue early a of caveat So

So as we're tight rope. you walking that indicated always in your question,

it more I But year. little additional think next adding the it. We we're of through to will right it a this space. guided science. that year, continue this not now, add probably back really crank at we and good through than up half will continue year. the It's a certainly add We're we'll perfect to as which we have for would will feel as I long demand we think we've and

On there space, place. the in incremental is -- bought Cognate That's CDMO manufacturing it, we of particularly therapy aspects capacity. on the cell particularly with space,

for additional client obviously So We demand. year we're finish both, to but the based space and the finish the only nature of add -- upon demand not have and next beyond fine.

of to things is Phase wanting those So III? launch up in some, all II? hinting to not? up. the are for Are Phase we And in and it or gear roll they they have us clients So about commercial

probably sufficient space certainly capacity this we'll to demand accommodate have and the year and of beginning add more for We there. year, the next

get in while it takes little XX nine is which Having and validated to the probably get the the two months limiting business, bit a tox in And a planning And addition. So the to years mean to it, demand. XX straightforward. the It's or space And be but XX to greenfield, its you've months planning not is space. about capacity just so, to maybe it's factor it's thing. is space. to we build factors because It's maybe built a maybe probably XX an right and really count, flip got now, of early is and shorter months. a cash. space CDMO Demand relatively rate-limiting head not don't I the right beautiful

getting be and a And accommodate of ahead do. to much too people short. it the it need sufficient we demand need us built when space of capacity we -- allows they when not have the trained hired getting too ahead So people token, around, there's to and accommodates nothing or same to the don't to space want many to sitting and the by

So act. a constant balancing it's

Robert Jones

Jim. Appreciate Thanks, your thoughts.

Jim Foster

Sure.

Operator

question Peterson Our Tycho next of comes JPMorgan. from

please. question Your

Tycho Peterson

about on Jim, about on vaccine you what's should intensifying. curious actually COVID. can you think we manufacturing, I'm baked thanks. dynamic. the Hey, how that COVID outlook talked testing quantify Curious if into

why portfolio. question it across that is think that Thermo and the Brammer. was about And has people Catalent I you to has Cognate, comes versus would as said MaSTherCell, million then with that about mind work one think year, last Paragon you we $XX

Cognate? competitive can a how little about So just talk bit you for you think about positioning

Jim Foster

RMS make was watching what we year Sure. we're out little were it a a out sense a year mean The and accost see we and investors. we last clearly numbers tightly going our and we year. were in this of because think it's COVID-related, had etc, Plus I were a I to for we're last a second trying what quarter, seeing to tough Microbial where that into other useful revenue this bit etc. down few in things We fall that called different year, I piece about that category don't than think, teased it.

COVID-related been is they perhaps probably variants who of At do get COVID-related already on some disease, continued be year, on into companies every people genre forward-going a be a year, be or it. the it. have going a of while and amount and others going to but I test meaningful year though, I antibodies was On last will to will testing modest, have ongoing they next vaccines. new there's always of booster treat that our think basis, going it the going monoclonal will Biologics know And least And flu-like. companies move not. and to there'll four modest some we're of if and I make Drugs because be. who business shots who being think to to and to therapeutics, like it work give don't vaccines continue basis, lot an antivirals. vaccinated perhaps

that break out be it going business. forward break just I think will or it to it all it's think because an don't I try So useful out ongoing to

work And I'm to question so that while besides with cell space. the Biologics, critical. the business say, and really us? a companies what really strong of us COVID-related no large you like I gene will and Why Well, work there's therapy two in are therapy molecule and products mentioned for really, gene principally antibodies and monoclonal someone think about there's be lots others would manufacturing that

have space, the manufacturing cell large the but sorry, we smaller therapy of cell are So suite are smaller have clients services. therapy -- size competitors who same as manufacturing around in we don't

to ability to through the a work our that. with work, continue process I think us continue way, clinic portfolio. from of to to the very, hope it's feature the research distinguishing So we add to by early very end-use development to -- And

to don't step So and hopefully, with more speed each at and with somebody The competition clients helps of a holistic else. approach. to market, they have pause work

Tycho Peterson

of of time increases DSA, how proprietary is some about out came call. those sustainable? managing curious you And just much trends follow-up, And the how that How And the you RMS, about I'm around trends talked the helpful. resurgence just on then the sustainability client called then a this pandemic? and you've think securing separately called do that well. of ahead outsourcing, Okay. as of GEMS, colonies. the pricing you you of of number for sustainability much space this At That's of from curious think out. about times

Jim Foster

good sustainability both really the of feel I of about them.

business clients. with and providing critically research. those important Those models produce to for bunch drug increasingly for a at are and nice So the GEMS growth of whole models, to has a us them for been There's least and associated producing a they're services decade. complicated basic

your our little more sites. across keep. through easily of pleased got to really yes, more given for environment, dome pleased pop We're COVID, and be there, funding doing other in break technologies, a to much made pretty though question. and that pricing, bit we're don't I is demand will modalities -- we're And of with a got that models, the immunotherapies we and a which think CRISPR I for gene really there. given any and which I incremental the of with globe because all us. And therapy new we even out. DSA demand the going the see rationale at cell We're not that like strong we continue the these think and to sophisticated, little the demand growth work

would I us clients Discovery, in at look Specifically take say, some caused to hadn't. that that a

happy. quite they're think I So

incremental as So work. new we D-Bio like retain think Retrogenix, will that like work. get we and And services add I we'll

So them; in the that I powerful capacity as and us getting as how think in said is hold pricing I clients see of remains there's utilized straight because and that really the as will visibility is maximizing our we'll planning; earlier, our of up. that space great terms for way would bottom indications for reason line. or would I for clients would the is terms better strong, more soften; think long no booking that slots that which paradigm -- earlier, demand it calendar

Tycho Peterson

you. Thank Okay.

Jim Foster

Okay.

Operator

of Stanley. next Ricky Our from Morgan Goldwasser question comes

Your question please.

Ricky Goldwasser

securing a Yes. tox the Hi. that on. time. mean is earlier quarter. to go back talking been the for Good long morning wanted the on and side around we've about to I comments this I congrats on room clients Jim, something

for So periods of takes that time sort play given are time, and your any you about -- of around to securing considering capacity? type of capacity to it XX right, or deals have longer conversations build with months, pay customers starting

Jim Foster

be would nice. That Yes.

situation. would and from needed a get until bit would be market of ago. it take-or-pay so had empty We we in couple I a basis capacity this logically that to the a they clients think they decade on for just never had I'm had that a to book pay -- line. follows over it book

others the XX% of times, to clinical relatively I cost and It's And and didn't one countless percentage a the that. the I for I hopeful worry cost was of would enough space big of of companies, but on clinic. development is sure you and it. for as spent that to of said the like drug commit so about R&D in trivial have to is I've being think if drug, cost a I developing of about the money mostly some drug tox and running

thoughts and clients that it. predict some with not. will that vibrations or about passing or I seem So I some to we've project happen had thinking reluctant that. a want to wouldn't about few questions as do whether just

seeing book slots earlier. Although people increasingly, we're not

the whatever reason, and slot. book they're I think happy I'm if with slots for they earlier

to back take-or-pay June. "Yes, them, may can't out want on requires -- to basis. it a do say say them start a space then say about or Let's And start study taking until it they further in we let's that we something the to September,"

that to market it think anything don't companies, I your So that big on is do those evidence particular, such possible. the have would I the that do deals. just in the horizon. are sorts drug And would say of support for question. that that's been dynamics I basis the reluctant we think any have concrete

Ricky Goldwasser

of been different and mix from I kind upping still you in segments. what's forecast of the long-term sort raising guide? beating And organic why your and then growth holding for goals mean, follow-up -- consistently back you've question, performance, of a of sort as business like your Considering

Jim Foster

-- our a in Nothing numbers weeks. going investor to conference give couple we're long-term in new of

So I think then. we'll to wait do that

holding So nothing is back. us

we a virtually have are companies have we and of all paradigm assessment what most a market modalities new drug the of biotech a companies. us. with think And footprint to work big the big the obviously, I the of good good funding and clients telling and understanding the and

base. have a good really So we installed

a numbers shortly. have we of out now new view be it, clear putting and we'll our So

Ricky Goldwasser

you. Thank Great.

Operator

Avendano Bank of next Our Juan of comes from America. question

Your please? question

Juan Avendano

update you up it is, on question. can the mix guess in been? studies an and strong the morning. How how Assessment backlog that question Hi, to you trend has building that in And of toxicology? Thank compare on toxicology years? good from how DSA give toxicology that I How you're seeing the prior Safety mix is for on specialty us and trends? general the does

Jim Foster

that. don't We any over have control

do You you usually specialty don't never, -- usually studies. get short-term don't don't work. wouldn't work a And you say long-term unless I toxicology studies general you've but unless done -- get get you you

is they bit the a specialty So We all that easier Action come profiles tandem. although both. not pricing in like on of are the dissimilar, kind work side.

like So way. it's XX-XX it probably around We the that range.

said, I control As it. we can't

once have stays you'll and say that balance in abundance in us while, balances like hear out that now. short-term time, ones So right we a and every of Typically, an enough long-term not feels it versa. or we're vice over

Juan Avendano

that on Can tracking synergies against seeing Discovery us long-term goal? follow-up Assessment? a on And And DSA the update or your how that you're the well. as give revenue pull-through across is Safety right it. Got between now you an and --

Jim Foster

we anything our who molecule thrilled develop compound. with help mean because processing of it us faster. question deep of discover because do a who don't that's understanding I trust have useful this did and number with quarterly no have never of And because science, we with did never c, us it's on I there's like clients productive really then on increasing a without a an Yes. did Discovery they and They could Discovery because or never the clients that Safety us clients. because too are a, kind they with clients to work to that think have work Safety basis, new to been finely b, or us, us or

develop a with us. will discovery Safety contract that clients with versa, time, amount that our words, them over So It the work vice think cutting-edge overreaching more increasingly, for whom We use and continue us and think have has just with that comfortable really to But significantly and drug. some as we great Discovery great continuing scientific and have discovery, the so open us clients with I think other we I or much. we that both are particularly much just way. a portfolio are In be have technologies grown of won't do I safety depth be to doing of don't to don't we the us significant before dangerous. with utilizing say would us

Juan Avendano

you. Thank Okay.

Operator

Dan Our next of question UBS. comes from Brennan

please. Your question

Dan Brennan

new components efficiencies. just first some maybe will, the maybe a you in you the of the Great. was out, Thanks you leverage one just just just impact with bit of line strong I that for the little guidance Just what impact would operating efficiencies, margins. called obviously, acquisitions? the from you're top leverage Could out on there? if know Maybe and providing? and the operating the question. from break taking What terms

David Smith

per right. neutral And this the we've earnings That's the the And year, different Retrogenix pretty is for given its Yes. given on deals share, Cognate margin well, broadly, size. pieces we've is and done. so

of in, the an as drag, a covering exception line a that's got as now. whole, what together So around the do well for it of -- this margin a that the drag. some Retrogenix. XX% we The isn't to that all had growth. program seeing a posted in we with working Manufacturing Charles very and overall with a kicking the the improvements break toward that put they're today, Cognate top increase With costs as increase is, But is businesses fall-through the out moment. majority by broadly, -- course, operational But margin, given there sort is of we've we've but and to I causing the we all upside efficiencies, seen, at Cognate good for to of upon margin It's River course, really itself. if of that because, got embedded top while fixed year, used the efficiency the this which line And not M&A do you're to of the on were we'll was stopped way the lot with with or I of also you've I well, yes, will we described. there. business, doing posting get But a that a time, that, help mean, year. performance we It our doing Once the to

Dan Brennan

I -- it be the think second you recovery. know drag it. talked grew on and I the last had expected below of the I there some given HemaCare. think one you about Got Maybe would pandemic just quarter,

What's the Just in guidance for baked the where stand now? remainder we 'XX do of in of for the year? HemaCare for terms

David Smith

small that said out, like What HemaCare I preprepared that had a we as out it's have broken of precise go year. for the donor had through it slower business. etc, do that haven't go of but strong than had we to the of issues it's year through the and we a improving beginning Well, sites, the we course, would in the And numbers. access HemaCare start we future. hoped, business that at the COVID still the we because relatively as see improving remarks And in just we year. see is to some a point fact

on small a business. the it's So this year, impact

Dan Brennan

I Microbial in from me. last Similarly, impact had prior this Got quarter, an quarter then the And excuse pandemic actually rebounded know you it. quarter. or the

what that there to Just we given catch-up like how that what the about to normalized think versus expectation segment? do ability business the you -- go for quarter this further for is saw

David Smith

Yes.

again, growth than in we So double-digit expected. called a as earlier we it's seen Microbial, the got out, nice we've improvement while

guidance full with that, course, equipment morning. headway to not be with course, pleased we've been install would We're an do access revised that But got continue that's we're of that. But And into to we factored all this in our of upside. the So as of clients. making new there.

Dan Brennan

maybe last just Jim. Great. on Cognate, And then one,

what think this and it. market? it's Just fronts. the in Sorry, end the it rate tag the you And I what missed XX%, or of specifically lot is on details those wondering for at you revenue if overall the the couldn't in gave given that that if year? be know Cognate think of higher deck this a correct? I of a growth I time you were both anticipating XX% And I deal, presentation. is why But than baked did

David Smith

That added $XXX helps. So revenue. million we in

Dan Brennan

XX%? given the -- wrong, And if did -- what of I in rate, terms year me growing market, talked the correct was you of I'm wondering I think you Just is, about opportunity it at is stronger. deal, certainly the end that kind a think, when the if not CAGR three

David Smith

an annual basis The rate was on XX% going growth Oh, forward. total

Dan Brennan

Got it. Thanks, David.

Operator

Anderson Evercore. of Our next comes Elizabeth question from

please. Your question,

Elizabeth Anderson

what because they're of time a moving how of taking characterize sort just era. post-pandemic in keeping that think delayed". all sort about sort I we through like the "oh, kind is think to of had Or your of to these you of had it their through guys. customers were or discovery little a Are tone sort get how would bit outsourcing, ask they're of people let's projects through Hi, more Or - program? conversations? what moving seeing sort changes you like of the just are like

Jim Foster

quite Solutions the difficulty systems. I mean and second when our positive, had academic they're placing except our clients research of in quarter some in were business Microbial closed, we model

remained open. except All open. were of sites a all our of handful, clients, virtually And our

to busy. our then all us. been the They're financed. capability have rest development have anything clients do of have clients no our well to discovered majority the of The that comes vast and So drugs internal to

business that and sort wouldn't of a them do, just We early money said and going our on demand to conference. chunk broadly gave at stage to we demand indications certainly as or as would our the I we is -- going So as what longer-term we say opposed our those enough and through where we move year. would of most portfolios, prosecute for our And board that don't see elements demand soften that change. this have clients been really it. dramatic robust soften earlier, portfolios any that there's And upon as a guidance is across increasingly based thoughts we the have intense investor

Elizabeth Anderson

seeing as or talked you any physical follow-up, couple And anything terms some in of -- the availability or on of the Or change any in That's and wages terms Okay. you of then expanding like a the helpful. capacity of that of of ago? versus out months infrastructure. cost Are it... a employees terms about capacity -- of pressures sense in constraints

Jim Foster

more We're hiring is that. the to for hiring a do everything because lot had hire of actually exceeding than demand planned we people people. we We're

on the earlier, depends So high-class locale. a it's It challenge. as geographic I said

to some, three the lots term drugs last the that locale, want an or to like lots people; locations XXX place work to probably And there's attractive for think over hire recruiting our we work countries. to like People easier on different best have geographic so It's of years. trying some it's greater do XX% of I people worked We competition. at. We're always tool. -- of that. are now, we

different and of the the than So count, kind it's places head different are for wage I said, as levels competition fluid.

always -- never to it stay that hard working we're trying pay to so or issue. we're up So ahead is an of

for the work. the say ultimate criticality not it's understand factor working So people we're in are anybody, of but just availability, our who that their is patients I'd really and rate-limiting business strong of

So very I'd a good say doing we're job.

quarter really the job good anticipate the year did with I think through a we the recruitment. half world. the improvement in first much of our We around the significant board back across pretty

to ahead of working we're so And stay it. hard

Elizabeth Anderson

Great. Thank you very much.

Operator

of Our Citi. next question Donnelly comes Patrick from

Your question please.

Patrick Donnelly

Thanks closed some about Cognate? now in should Great. conversations therapy it's and more interest to term? gene little we cell of more customer gene that those like can piece. guys. Have kind therapy be HemaCare Or cell another areas end-to-end Cellero understand of benefits Maybe you and just you're now gene but and business one long still and you cell an a therapy your around on the seen expect you've any player? early days, I that talk increased

Jim Foster

it mean is I early.

lack with revenues the that because the So Cellero of access in donors, to in we or old. month of a HemaCare combination up two have new. relatively more Cognate's It's slowly coupled -- the and of quarter fact first

to So tell. I think early it's

very, virtually, no very thesis use clients but a build the that very one, through powerful. themselves. process through doubt going clients strong early We commercial and stuff going up clinic client's to no No out development -- to us quantities is is to process the who in this the scale have build can starting

is marketplace think I the competitive for attractive us.

we everyone, ability or think pharmacology ability some clients -- uptake some portfolio streams based but upon a across small products those services, sell have it's including testing, because us. the companies in testing, microbial Look, it's biologic and them, cell more a dozen and -- the business based half We different work time particularly different to therapy unique different safety for business. I business, upon definitely a portfolio including it's else of a that a big becoming gene for we providers model -- clients biotech business a or are provide desire than no everything and of solution do. including including research to across whole have so resonating particularly and our to holistic conversations of the and suite our of services very comprehensive, with don't they the testing,

more And nonclinical don't our they that so don't because And players. being want our we b, it do they multiple and to whole CRO don't do have largest to they to the work with about have thesis can so clients. a, is for themselves

Patrick Donnelly

and Todd you. Dave, Got Thanks Jim.

Operator

Our final question comes Hill from of Deutsche Bank. George

please? question Your

George Hill

this talk your Maxi on some dynamics It's if to thoughts about in change in Hi. create recent vertical Could innovation George. deals dynamics -- later-stage and research you move for upstream trend is competitive following space on the in services? there opportunities into industry the

Jim Foster

Yes.

I I that. followed think

the in, referring You not side business, consolidation the than side. saw look, we quickly. we said the But but the which to, consolidation in heavily on is participate different that preclinical of no that really yes, only really the clinical you're

different as know, have Safety business. and nine a different eight in probably So XX we you or the acquisitions have We sites

geographic the and had so footprint. whole that So and all capabilities directly we consolidating industry more we and a -- depth is had side with broader business that acquisition scientific

So you see phenomenon are in exact the seeing clinical space. same and to will the continue

probably. it know three it up, it started, don't continue. two Now that will where players end think or I will I

for I look, often. think what always about it -- discuss look, when us, say, look means question often. at space portends that or Look clinical Your we we the I

capability, And think we're is therapy. sold a used it's CDMO with that to back which know I clinical cell in -- gene clinical you have now the because we in and it molecule, under scale. small small we which

So CDMO is we clinical two one space. the sort is big of space, moves: have one

like it, toe and space at dipped the CDMO that on So we side. into therapy cell least the

should that, and it. there's I guess. like On the the unless I a are clinical need, It could think that doesn't a contemplate -- don't that even requesting we client we side, make seem clients move do

has preclinical buy that from Covance, failed clients the I way. company work contracts them through and clinic I all nor basis the So only that do capabilities clinical don't is think to buys preclinical it's think that years. have the on way a that's a experiment. Nobody

about in of the contemplate we wallet. with haven't them. So that came client's a decade And a it any together. a share although would had the No I even provide last me the think CRO clinical of us move, bigger conversation that one's ever called clinical with don't paying CRO together would

the to Having time preclinical never site thinking I or until that, never the that aren't buying have in since that see any So a and doing would and us desirous us get to for rationale attractive. way be learned clients But clinical of people said not that about changes, logical any that way long of ago that, together. I other anything. say side don't

when company happens, clients quotient multiple would So and one at will I that both. do don't the we'll explore. If to change know point companies demand what or want and

Todd Spencer

the call. speaking May We events, you the look upcoming conference joining you you. Thank our on Day concludes during forward today. virtual the us including Thank call. our with to that concludes Investor on Well, call This for investor XX. conference

Operator

Instructions] [Operator

Charles River Laboratories International (CRL) 4 May 212021 Q1 Earnings call transcript